Skip to main content

Table 3 Most common treatment-related adverse events (ITT-population: n = 77)

From: Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience

 

All grades

Grades ≥ 3*

 

N

%

N

%

Any event

38

49.4

23

29,9

Leukopenia

17

22.1

13

16.9

Anemia

13

16.9

5

6.5

Thrombocytopenia

6

7.8

1

1.3

Neutropenia

2

2.6

1

1.3

Elevated liver enzymes‡

16

20.8

5

6.5

Fatigue

12

15.6

1

1.3

Pain§

10

13.0

3

3.9

Constipation

9

11.7

4

5.2

Nausea

9

11.7

2

2.6

Constitutional symptoms

4

5.2

3

3.9

Infection†

3

3.9

3

3.9

Mucositis

3

3.9

0

0.0

Vomiting

2

2.6

2

2.6

Neutropenic infection

1

1.3

1

1.3

  1. Adverse events occurring in at least 3 patients are listed. For completeness neutropenia and vomiting have been added
  2. *3 potentially treatment-related deaths were reported: infection (relation possible), infection (relation likely), hypoxia (relation possible)
  3. ‡Summarizing elevated alanine-aminotransferase (ALT), aspartate-aminotransferase (AST), alkaline phosphatase and gamma-glutamintranferase (GGT)
  4. §Pain in abdomen, extremity, head, joint or stomach
  5. †Infections with normal absolute neutrophil count (ANC)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us